Your SlideShare is downloading. ×
Global diabetes market trends & future forecast – diabetes drug (anti diabetic drug), insulin, dpp-iv, glp-1
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Global diabetes market trends & future forecast – diabetes drug (anti diabetic drug), insulin, dpp-iv, glp-1

2,190
views

Published on

http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes-drug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27 …

http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes-drug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27

Renub Research has announced the addition of "Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1" report to its offering


Click here to view the report details: http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes-drug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27

For more information visit: http://www.renub.com/


Contact Us

Ankit Mishra
Relationship Manager
Sales & Marketing Div
Renub Research
Email: info@renub.com
Phone: +1-678-302-0700 (USA) +91-120-254-5750 (India)
Web: http://www.renub.com/

About US:

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others

Published in: Business, Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,190
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
70
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Publisher: Renub Research Published: June 2010
  • 2. © Renub Research Page 2 of 10 Report Details “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:  Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast  Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence  Region wise Diabetes Health Expenditure and Mortality  Top 10 Countries Diabetes Population and Future Forecast  Top 5 Countries Diabetes Drug Market and Future Forecast  Top 7 Countries Insulin Market and Future Forecast  Top 6 Diabetes Drug Brands (Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market  Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market  Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market  Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market Research Highlights  USA controls more than 50% of the total Diabetes Drug market share in 2009  Global Insulin Market is estimated to reach around US$ 17 Billion by 2013  China will have the second highest Insulin market share by 2012 replacing Germany  DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015  GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015  Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
  • 3. © Renub Research Page 3 of 10  Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.  Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017  Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists  China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009  Japan Insulin market is expected to be more than US$ 1 Billion by 2010 Key Drugs Analyzed Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus, GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide Data Sources Information and data in this report has been collected from various printable and non- printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.
  • 4. © Renub Research Page 4 of 10 Table of Contents 1. Executive Summary 2. Global Diabetes Market 2.1 Global – Diabetes Drug Market & Future Forecast 2.2 Global – Insulin Market & Future Forecast 2.3 Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India) 2.4 Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan, USA, India) 2.5 Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast 2.6 Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast 3. Global – Top 6 Diabetes Drug Brands Market Performance 3.1 Avandia – Past & Present Market 3.2 Actos – Past, Present & Future Forecast 3.3 Amaryl – Past, Present & Future Forecast 3.4 Avandamet – Past, Present & Future Forecast 3.5 Prandin/Novonorm – Past & Present Market 3.6 Starlix – Past, Present & Future Forecast 4. Global – Top 9 Insulin Brands Market Performance 4.1 Novomix – Past, Present & Future Forecast 4.2 Novorapid – Past, Present & Future Forecast 4.3 Levemir – Past, Present & Future Forecast 4.4 Degludec – Yet to be Launched - Future Forecast 4.5 Degludecplus – Yet to be Launched – Future Forecast 4.6 Humalog – Past & Present Market 4.7 Humulin – Past & Present Market 4.8 Apidra – Past, Present & Future Forecast 4.9 Lantus – Past, Present & Future Forecast
  • 5. © Renub Research Page 5 of 10 5. Global – DPP-IV Inhibitors Brands Market Performance 5.1 Januvia – Past, Present & Future Forecast 5.2 Onglyza – Past, Present & Future Forecast 5.3 Alogliptin – Yet to be Launched – Future Forecast 5.4 Galvus – Past, Present & Future Forecast 5.5 DPP-IV Inhibitors – In Trial Phases 6. Global – GLP-1 Agonists Brands Market Performance 6.1 Byetta – Past, Present & Future Forecast 6.2 Victoza – Past, Present & Future Forecast 6.3 Exenatide LAR – Yet to be Launched – Future Forecast 6.4 Syncria – Yet to be Launched – Future Forecast 6.5 Taspoglutide – Yet to be Launched – Future Forecast 7. Regional Estimates for Diabetes 7.1 Diabetes – Population & Prevalence 7.2 Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.3 Mortality – Due to Diabetes 7.4 North America & Caribbean Region 7.4.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.4.2 Healthcare Expenditure & Type 1 Diabetes 7.4.3 Mortality 7.5 Middle East and North African Region 7.5.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.5.2 Healthcare Expenditure & Type 1 Diabetes 7.5.3 Mortality 7.6 South-East Asian Region 7.6.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.6.2 Healthcare Expenditure & Type 1 Diabetes 7.6.3 Mortality 7.7 European Region 7.7.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.7.2 Healthcare Expenditures & Type 1 Diabetes
  • 6. © Renub Research Page 6 of 10 7.7.3 Mortality 7.8 South and Central American Region 7.8.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.8.2 Healthcare Expenditures & Type 1 Diabetes 7.8.3 Mortality 7.9 Western Pacific Region 7.9.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.9.2 Healthcare Expenditures & Type 1 Diabetes 7.9.3 Mortality 7.10 African Region 7.10.1 Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence 7.10.2 Healthcare Expenditure & Type 1 Diabetes 7.10.3 Mortality 8. Global – Top 10 Diabetic Countries Performance 8.1 Number of People in Top 10 Diabetic Place 8.2 Prevalence of Diabetes in Top 10 Countries 8.3 India 8.3.1 Diabetes Population & Future Scenario 8.3.2 India – Diabetes Drug Market & Future Forecast 8.3.3 India-Insulin Market & Future Forecast 8.4 China 8.4.1 Diabetes Population & Future Scenario 8.4.2 Diabetes Drug Market & Future Forecast 8.4.3 China Insulin Market & Future Forecast 8.5 United States 8.5.1 Diabetes Population & Future Scenario 8.5.2 Diabetes Drug Market & Future Forecast 8.5.3 Insulin Market & Future Forecast 8.6 Brazil 8.6.1 Diabetes Population & Future Scenario 8.6.2 Diabetes Drug Market & Future Forecast 8.7 Russia 8.7.1 Diabetes Population & Future Scenario 8.7.2 Insulin Market & Future Forecast
  • 7. © Renub Research Page 7 of 10 8.8 Japan 8.8.1 Diabetes Population & Future Scenario 8.8.2 Diabetes Drug Market & Future Forecast 8.8.3 Insulin Market & Future Forecast 8.9 Germany 8.9.1 Diabetes Population & Future Scenario 8.9.2 Insulin Market & Future Forecast 8.10 Mexico 8.10.1 Diabetes Population & Future Scenario 8.10.2 Insulin Market & Future Forecast 8.11 Indonesia 8.11.1 Diabetes Population & Future Scenario 8.12 Pakistan 8.12.1 Diabetes Population & Future Scenario
  • 8. © Renub Research Page 8 of 10 Order Form Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com Format Report Title: Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1 Single User (Email from Publisher) Hard Copy (Mail Delivery) CD – Rom (Mail Delivery) Global Site License (Multiple User License) US$ 1,100 US$ 1,250 US$ 1,250 US$ 1,600 For ordering this report: Three easy ways to place your order: 1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes- drug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27 2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=27&pid=1092 To pay by Wire Transfer, please, fill in your contact details in the form below:
  • 9. © Renub Research Page 9 of 10 Bank Details Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India Contact Information First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:
  • 10. © Renub Research Page 10 of 10 3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st Floor C-86, Sector -10 Noida - 201301 Uttar Pradesh India Phone: +91-120-4219-822, 4249-780 For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA) Follow Us Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research Twitter: http://twitter.com/RenubResearch

×